Parsons Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMLX
SL
Parsons Capital Management's AMLX Position: Q3 2026 in Review
Parsons Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 33% in Q3 2026, buying an estimated $187K and bringing the position to 28,682 shares worth $835K. The position accounts for 0.04% of the portfolio, ranked #318.
Parsons Capital Management first reported a position in AMLX in Q3 2022 and has held it in 17 quarters since. The position peaked at $1M in Q4 2022. 173 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.
- Parsons Capital Management held 28,682 shares of Amylyx Pharmaceuticals worth $835K as of Q3 2026.
- Parsons Capital Management bought 7,037 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $187K.
- Amylyx Pharmaceuticals made up 0.04% of Parsons Capital Management's portfolio in Q3 2026, its #318 holding.
- Parsons Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 17 quarters since.
- Parsons Capital Management's Amylyx Pharmaceuticals position peaked at $1M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.
Based on Parsons Capital Management's 13F filing for Q3 2026, filed 28 Oct 2026.